Raffles Medical Group Ltd
Raffles Medical Group Ltd (RAFLF) Financial Performance & Income Statement Overview
Review Raffles Medical Group Ltd (RAFLF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Raffles Medical Group Ltd (RAFLF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Raffles Medical Group Ltd RAFLF financial performance.
| Metric | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $182.84M | $182.84M | $127.75M | $123.32M |
| Cost of Revenue | $100.71M | $100.71M | $52.25M | $50.44M |
| Gross Profit | $82.14M | $82.14M | $75.50M | $72.88M |
| Gross Profit Ratio | $0.45 | $0.45 | $0.59 | $0.59 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $41.77M | $41.77M | $53.12M | $51.27M |
| Operating Expenses | $61.50M | $61.50M | $60.69M | $58.58M |
| Total Costs & Expenses | $162.21M | $162.21M | $112.94M | $109.03M |
| Interest Income | $5.30M | $1.07M | $3.96M | $703689.00 |
| Interest Expense | $3.16M | $0.00 | $2.54M | $0.00 |
| Depreciation & Amortization | $9.36M | $9.36M | $2.58M | $2.49M |
| EBITDA | $30.003M | $30.003M | $14.52M | $14.02M |
| EBITDA Ratio | $0.16 | $0.16 | $0.11 | $0.11 |
| Operating Income | $20.64M | $20.64M | $11.94M | $11.53M |
| Operating Income Ratio | $0.11 | $0.11 | $0.09 | $0.09 |
| Other Income/Expenses (Net) | $1.07M | $1.07M | $3.60M | $3.47M |
| Income Before Tax | $21.71M | $21.71M | $15.54M | $15.000M |
| Income Before Tax Ratio | $0.12 | $0.12 | $0.12 | $0.12 |
| Income Tax Expense | $6.24M | $6.24M | $3.92M | $3.78M |
| Net Income | $15.32M | $15.32M | $11.48M | $11.08M |
| Net Income Ratio | $0.08 | $0.08 | $0.09 | $0.09 |
| EPS | $0.008 | $0.008 | $0.006 | $0.006 |
| Diluted EPS | $0.008 | $0.008 | $0.006 | $0.006 |
| Weighted Avg Shares Outstanding | $1.89B | $1.89B | $1.87B | $1.87B |
| Weighted Avg Shares Outstanding (Diluted) | $1.89B | $1.89B | $1.87B | $1.87B |
The company's financials show resilient growth, with revenue advancing from $123.32M in Q3 2023 to $182.84M in Q2 2024. Gross profit remained healthy with margins at 45% in Q2 2024 compared to 59% in Q3 2023. Operating income hit $20.64M last quarter, sustaining a consistent 11% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $30.003M. Net income rose to $15.32M, while earnings per share reached $0.008. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan